TIME SENSITIVE - WOEMA Webinar 12/21/16 - The California DWC Formulary: An Introduction
Posted over 8 years ago by Denise Souza
WOEMA’s Education Committee offers CME Webinars on topics relevant to the practice of occupational and environmental medicine. These webinars can be accessed by calling a toll-free 800 number and viewing the Powerpoint presentation using your Internet browser from your own computer. WOEMA members will be notified in advance of the dial-in phone number and the URL link to access the slides. When the CME Webinar is offered live, members will have the opportunity to send questions to the presenter and have those answered in real-time on the live broadcast.
WOEMA CME Webinar Registration Fees
WOEMA/ACOEM Member – Free
Non-Member Physician – $20
Non-Member, Non-Physician – $15
Click here to listen/view past webinar presentations.
TOPIC: The California DWC Formulary: An Introduction
Scheduled to air on December 21, 2016 at 12:00 pm PT
Speaker: Robert L. Goldberg, MD, FACOEM
The 2017 implementation of the California DWC drug formulary will impact care for hundreds of thousands of injured workers. Thus great attention has been turned to the current draft regulations, which add an important layer of clinical context to guide drug therapy. The formulary is notably linked to the California Medical Treatment Utilization Schedule (MTUS) and driven by the American College of Occupational and Environmental Medicine (ACOEM) treatment guidelines. The DWC adoption of a closed drug formulary grounded in such high-quality evidence-based guidelines will place drug therapy decisions within the context of the injury or condition being treated, rather than the availability of the medication alone. Dr. Robert Goldberg will speak to the development of the DWC formulary, its potential clinical and cost benefits, provide insight into its functionality and application, and discuss important considerations for implementation.
Learning Objectives – Participants will be able to:
- Summarize the development of the formulary from evidence-based occupational medical treatment guidelines
- Explain the potential clinical and cost benefits of a closed drug formulary supported by evidence-based guidelines
- Describe the considerations that are important to the successful implementation and adoption of a state-based formulary
- Describe the functionality of the formulary and the supporting tools to make prescribing decisions for injured workers
Dr. Robert Goldberg is the Chief Medical Officer of Healthesystems and the developer of the ACOEM/Reed formulary. Board -certified in Occupational Medicine and a former Vice-Chair, Occupational Medicine of the American Board of Preventive Medicine, he is a nationally-recognized expert in the prevention and treatment of work-related injuries. He is also a Past-President of ACOEM and WOEMA and was a Professor of Medicine and the Residency Director in the Division of Occupational and Environmental Medicine at UCSF.
CREDIT: WOEMA is accredited by the Institute of Medical Quality/California Medical Association to provide continuing medical education for physicians. WOEMA takes responsibility for the content, quality, and scientific integrity of this CME activity.
WOEMA designates this live internet activity, when combined with completion and submission of the on-line questionnaire, for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This credit may also be applied to the CMA Certification in Continuing Medical Education.